Navigation Links
Positron Recieves Indiana Board of Pharmacy License
Date:12/19/2011

FISHERS, Ind., Dec. 19, 2011 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), a leading molecular imaging company specializing in the field of nuclear cardiology is pleased to announce that on December 16, 2011, the Company received a nuclear pharmacy license from the Indiana Board of Pharmacy for the Company's Crown Point, Indiana manufacturing facility.

The Indiana Board of Pharmacy license completes the requirements necessary to amend its NRC license to allow Positron to manufacture and distribute radiochemicals and radiopharmaceuticals throughout the United States.  The Company will begin to produce Indium 111 Oxyquinoline for customer evaluation and commercial sale.

"We are pleased to receive this approval as it will allow our Crown Point facility to become fully licensed and operational as a radiochemical manufacturing facility," said Scott Stiffler, Positron's Vice President of Pharmaceuticals. "The Crown Point facility provides an ideal site for the manufacturing and development of radiopharmaceuticals and radiochemicals.  The revenue generated from our Indium Oxyquinoline sales will allow Positron to expand its current product offerings. I'm pleased with the team's efforts and execution at Crown Point of this significant milestone."

About Positron: Positron Corporation is a leading molecular imaging company providing innovative nuclear medicine technologies and services that are reshaping the field of nuclear cardiology.  Through proprietary PET imaging systems and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine.  Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.

Forward Looking Statements: Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.  Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Positron Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
2. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
3. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
4. New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors
5. Alliance Imaging Offers Mobile Positron Emission Mammography (PEM) Imaging to its Florida Customers
6. Researchers at MD Anderson Show That Positron Emission Mammography (PEM) Helps Evaluate Early Response to Neoadjuvant Chemotherapy
7. Naviscan Positron Emission Mammography Technology Highlighted at the Society of Nuclear Medicine Annual Meeting
8. Preliminary Research Results Suggest up to 70% Reduction in Dose for Positron Emission Mammography Imaging
9. Global PET SPECT Market (Positron Emission Tomography) & SPECT (Single Photon Emission Computed Tomography) to be US$ 10.3 Billion by 2015
10. Naviscan Announces European Launch of Positron Emission Mammography
11. Study Shows Positron Emission Mammography (PEM) is Easy for Breast Imagers to Learn Regardless of Experience
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... Direct-to-consumer digital marketing ... and 65% increase in consumable sales, quarter-over-quarter ... DRIO ), a leader in digital health ... Dario™ Blood Glucose Monitoring System, an all-in-one diabetes meter, ... and minimally invasive smart diabetes management solution. ...
(Date:1/23/2017)... plc, (NYSE: AGN ), a leading global pharmaceutical ... Academy (IHA). Designed to inspire a long-term commitment to Headache ... three-day, intensive overview on research and treatment options. This is ... since the inception of IHA in North America ... in 2014. "Allergan is dedicated ...
(Date:1/23/2017)... 2017  Using Astute Medical,s NephroCheck Test ... acute kidney injury (AKI) after open-heart surgery and ... guidelines significantly improved outcomes by reducing the ... 33 percent, according to a study ... Care Medicine. Experience the interactive ...
Breaking Medicine Technology:
(Date:1/24/2017)... ... January 23, 2017 , ... The January 2017 issue ... three-year outcome study on how outdoor behavioral healthcare (OBH) – also known as wilderness ... interpersonal difficulties while experiencing an increased sense of purpose both during and after treatment. ...
(Date:1/24/2017)... ... January 23, 2017 , ... During the January ... Carol Francis, Psychologist in the South Bay area , explained “Watching Women’s Marches ... people and by all people shines as a bright beacon of determination and ...
(Date:1/23/2017)... ... January 23, 2017 , ... A Northwestern Pennsylvania ... domain address. Alpine Springs Rehabilitation & Recovery Center’s new website can be found ... along with its redesigned and retooled website. The treatment center has also revamped ...
(Date:1/23/2017)... ... 23, 2017 , ... Ultimate Medical Academy today announced the ... held March 23-25, 2017 in Tampa, and reminded educators and education leaders to ... include Dr. Michelle R. Weise, executive director of the Sandbox Collaborative, the R&D ...
(Date:1/23/2017)... ... 23, 2017 , ... Wooden and plastic balance boards have been around since at least the ... Board is the first and only balance board to use a patent-pending design featuring ... at the same time as well as skill-level adjustable for all ages and abilities. ...
Breaking Medicine News(10 mins):